The interplay between SLC1A5 and SLC7A5, belonging to the SLC7 family of glutamine antiporters, was previously suggested, pointing towards the enhanced entry of essential amino acids via SLC7A5, activated by Gln flux through SLC1A5, as a strategy contributing to cancer progression [66]. The gene discussed is SLC7A5; the disease is cancer.